These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 8862840)

  • 1. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients.
    Blanchet PJ; Allard P; Grégoire L; Tardif F; Bédard PJ
    Can J Neurol Sci; 1996 Aug; 23(3):189-93. PubMed ID: 8862840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacology of levodopa-induced dyskinesia.
    Nutt JG
    Ann Neurol; 2000 Apr; 47(4 Suppl 1):S160-4; discussion S164-6. PubMed ID: 10762144
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-homogeneous effect of levodopa on inhibitory circuits in Parkinson's disease and dyskinesia.
    Barbin L; Leux C; Sauleau P; Meyniel C; Nguyen JM; Pereon Y; Damier P
    Parkinsonism Relat Disord; 2013 Feb; 19(2):165-70. PubMed ID: 23000298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cascade of levodopa dose and weight-related dyskinesia in Parkinson's disease (LD-WD-PD cascade).
    Sharma JC; Macnamara L; Hasoon M; Vassallo M; Ross I
    Parkinsonism Relat Disord; 2006 Dec; 12(8):499-505. PubMed ID: 16935018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of etybenzatropine and diazepam on levodopa-induced diphasic dyskinesias in Parkinson's disease.
    Pourcher E; Bonnet AM; Kefalos J; Dubois B; Agid Y
    Mov Disord; 1989; 4(3):195-201. PubMed ID: 2779590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa.
    Rascol O; Brooks DJ; Korczyn AD; De Deyn PP; Clarke CE; Lang AE
    N Engl J Med; 2000 May; 342(20):1484-91. PubMed ID: 10816186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A combined pharmacokinetic/pharmacodynamic model of levodopa motor response and dyskinesia in Parkinson's disease patients.
    Simon N; Viallet F; Boulamery A; Eusebio A; Gayraud D; Azulay JP
    Eur J Clin Pharmacol; 2016 Apr; 72(4):423-30. PubMed ID: 26936272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Levodopa-induced dyskinesia in 176 patients with Parkinson's disease].
    Rocha MS; Andrade LA; Ferraz HB; Borges V
    Arq Neuropsiquiatr; 1995 Dec; 53(4):737-42. PubMed ID: 8729765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease.
    Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F;
    Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential progression of motor impairment in levodopa-treated Parkinson's disease.
    Goetz CG; Stebbins GT; Blasucci LM
    Mov Disord; 2000 May; 15(3):479-84. PubMed ID: 10830412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Profile of levodopa-induced dyskinesia in patients of Parkinson's disease: a record based study.
    Choudhury S; Pradhan R; Paul P; Das M; Gupta A; Ghosh P; Chatterjee S
    Neurol Res; 2014 Sep; 36(9):841-6. PubMed ID: 24601722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study.
    Stocchi F; Rascol O; Destee A; Hattori N; Hauser RA; Lang AE; Poewe W; Stacy M; Tolosa E; Gao H; Nagel J; Merschhemke M; Graf A; Kenney C; Trenkwalder C
    Mov Disord; 2013 Nov; 28(13):1838-46. PubMed ID: 23853029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating and preventing levodopa-induced dyskinesias: current and future strategies.
    Durif F
    Drugs Aging; 1999 May; 14(5):337-45. PubMed ID: 10408734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improvement of levodopa-induced dyskinesia by propranolol in Parkinson's disease.
    Carpentier AF; Bonnet AM; Vidailhet M; Agid Y
    Neurology; 1996 Jun; 46(6):1548-51. PubMed ID: 8649546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blink reflex in Parkinson's disease with levodopa-induced dyskinesia.
    Iriarte LM; Chacon J; Madrazo J; Chaparro P
    Funct Neurol; 1989; 4(3):257-61. PubMed ID: 2792861
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ventrolateral thalamotomy for dyskinesia following levodopa therapy of Parkinson's disease.
    Lee ST; Lu CS
    J Formos Med Assoc; 1996 Dec; 95(12):943-5. PubMed ID: 9000814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.
    Horstink MW; Zijlmans JC; Pasman JW; Berger HJ; van't Hof MA
    J Neurol Neurosurg Psychiatry; 1990 Mar; 53(3):224-6. PubMed ID: 2324754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Levodopa-induced dyskinesia: clinical observations.
    Friedman A
    J Neurol; 1985; 232(1):29-31. PubMed ID: 3998772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Tandospirone citrate, a selective 5-HT1A agonist, alleviates L-DOPA-induced dyskinesia in patients with Parkinson's disease].
    Kannari K; Kurahashi K; Tomiyama M; Maeda T; Arai A; Baba M; Suda T; Matsunaga M
    No To Shinkei; 2002 Feb; 54(2):133-7. PubMed ID: 11889759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.